AlphAIalphai — Financial news for AI agents
BenzingaOCT 173 min read$WHWK

Whitehawk Therapeutics Dips Over 8% In After-Hours Trading Despite New Tempus AI Partnership - Whitehawk Therapeutics (NASDAQ:WHWK)

Whitehawk Therapeutics Inc. ( NASDAQ:WHWK ) dropped 8.81% in after-hours trading Thursday, closing at $2.38, after announcing a multi-year collaboration with Tempus AI. Check out the current price of WHWK stock here. WHWK closed Thursday at $2.61, up 23.70% on the day, according to Benzinga ...

Original reporting
Benzinga · Mohd Haider
Published Oct 17, 2025, 4:44 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 17, 2025, 5:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Whitehawk Therapeutics Dips Over 8% In After-Hours Trading Despite New Tempus AI Partnership - Whitehawk Therapeutics (NASDAQ:WHWK) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$WHWKNeutralLow
01

Why it matters

The partnership initially boosted investor optimism, but profit-taking and skepticism led to an after-hours decline, reflecting mixed market sentiment.

02

Market read

The news has short-term relevance for WHWK and related biotech stocks, with limited broader market impact.

03

What to watch

Broader market conditions, sector rotation, and upcoming earnings reports could influence stock performance beyond news headlines.

Timing: Immediate to short-term

Background

Whitehawk Therapeutics announced a multi-year collaboration with Tempus AI, aiming to leverage AI for biotech advancements.

Company-level read

Ticker impact

$WHWKNeutralMedium confidence
Context

High relevance due to recent price movement and partnership news.

Expected impact

Short-term volatility with potential for a rebound if partnership prospects are realized; medium-term outlook remains uncertain.

Evidence & confidence

The initial positive reaction was driven by partnership news, but the subsequent decline suggests profit-taking or skepticism. Technical levels and broader market conditions should be monitored for clearer signals.

$TEMBullishMedium confidence
Context

Moderate relevance; sentiment indicates a somewhat bullish outlook, but limited direct impact from the news on TEM's stock.

Expected impact

Minimal impact expected; possible slight positive bias if partnership benefits are perceived.

Evidence & confidence

The partnership may indirectly benefit TEM, but current data does not suggest a significant immediate price movement.

Market effects

Sector

Potential positive sentiment for biotech and pharmaceutical sectors due to AI collaborations.

Regional

Limited; primarily affects US-based biotech stocks.

Global

Low; specific to US biotech sector and individual companies.

Counterpoint

What could challenge this read

The decline may be a temporary profit-taking move; the partnership could still lead to positive long-term developments.

Key entities

  • Company
    Whitehawk Therapeutics

    Biotech company focusing on innovative therapies.

  • Partnership Entity
    Tempus AI

    AI technology provider collaborating with Whitehawk.

Read at source← All news

Related articles

AUG 27
$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

insidermonkey.com3 min
AUG 24
$TEMMedAI 8/10

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. (NASDAQ: TEM) received FDA clearance for its AI product, Tempus ECG-PH, designed to detect signs of pulmonary hypertension from standard ECGs. This is the third FDA-cleared cardiovascular device in Tempus' portfolio, aiming to help clinicians identify at-risk patients earlier. The product analyzes ECG data but is not intended for standalone diagnosis.

biospace.com2 min
AUG 23
$TEMHighAI 8/10

Why Tempus AI Skyrocketed This Week

Tempus AI (TEM) shares rose 39.5% this week after Merck and Moderna reported positive Phase 3 trial data for their cancer vaccine, which uses technology from Personalis, a company Tempus is acquiring. Tempus's market cap is $13B, and its stock is still down about 10% over the past year. The acquisition is expected to close late 2024 or early 2027.

fool.com2 min
AUG 22
$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

stockstotrade.com3 min